From this rigorous approach, we discover for the first time a causal link between APOE4, TGF-β signaling, cerebrovascular fibrosis, and AD pathology, opening a path to new therapeutic opportunities in the treatment and prevention of AD in high-risk individuals. This evidence concerns the gene APOE and Alzheimer disease.